Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Specialty chemicals supplier Azelis has acquired Barcelona-based Solchem Nature, reinforcing its presence in the Spanish nutraceuticals market.
read more
Fexuclue is a novel potassium competitive acid blocker approved as a new treatment for adults with erosive esophagitis of all grades.
read more
Rinvoq is the first and only oral JAK inhibitor approved in the EU, Iceland, Liechtenstein and Norway, for the treatment of adult patients with GCA.
read more
Pittsburgh-based generic drugmaker has reached a nationwide settlement framework to resolve opioid-related claims against the company and its subsidiaries.
read more
The CDMO is adding a commercial-scale spray dryer and a Gerteis dry granulation system at its facility in Gainesville, Georgia.
read more
DHL will acquire Cryoport’s CRYOPDP, a specialty courier providing logistics services for clinical trials, biopharma and cell and gene therapies.
read more
Novo has inked a licensing deal for Lexicon’s first-in-class, oral non-incretin preclinical candidate in obesity and associated metabolic disorders.
read more
Vykat XR is the first approved drug to address the insatiable hunger associated with the rare condition.
read more
Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years.
read more
The oversubscribed financing was co-led by Novo Holdings and Jeito Capital and supported by existing investors, including Eli Lilly.
read more
The nod marks the third FDA approval for oral Fabhalta and the first and only treatment approved in C3 glomerulopathy.
read more
The partners received a second CRL from the FDA regarding their combination treatment of rivoceranib and camrelizumab for hepatocellular carcinoma.
read more
The Vancouver-based biotech prepares to initiate a phase 1/2a clinical trial for its MEAI-based oral drug candidate in the U.S. and Israel.
read more
The study compared an oral version of Eli Lilly’s Zepbound, created with Lexaria’s patented drug delivery technology, to conventional injected Zepbound.
read more
According to study from BCC Research, global softgel capsules market is expected to grow from $7.9 billion in 2024 to $11.5 billion by the end of 2029.
read more